Meeting
2021 ASCO Annual Meeting
A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival.
Authors
Masatoshi Kudo
Kindai University Faculty of Medicine, Osaka, Japan
Masatoshi Kudo , Kiyoshi Hasegawa , Yoshikuni Kawaguchi , Tadatoshi Takayama , Namiki Izumi , Naoki Yamanaka , Mitsuo Shimada , Masahumi Inomata , Shuichi Kaneko , Hideo Baba , Kazuhiko Koike , Masao Omata , Masatoshi Makuuchi , Yutaka Matsuyama , Norihiro Kokudo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
000001795
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 4093)
DOI
10.1200/JCO.2021.39.15_suppl.4093
Abstract #
4093
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 Gastrointestinal Cancers Symposium
A randomized controlled trial to compare the effectiveness between surgery and radiofrequency ablation for hepatocellular carcinoma: SURF trial.
First Author: Kiyoshi Hasegawa
Poster
2022 ASCO Annual Meeting
A multicenter, non-randomized, controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF-Cohort Trial): Analysis of overall survival.
First Author: Tatsuya Yamashita
Poster
2020 ASCO Virtual Scientific Program
A multicenter nonrandomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF cohort trial).
First Author: Ryosuke Tateishi
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of atezolizumab/bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma (HCC) according to the type of disease progression.
First Author: Spyridon Pantzios